139 related articles for article (PubMed ID: 25132652)
1. Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia.
Langabeer SE; Haslam K; McMahon C
Pediatr Blood Cancer; 2015 Jan; 62(1):175-6. PubMed ID: 25132652
[No Abstract] [Full Text] [Related]
2. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
3. JAK2, MPL, and CALR mutations in children with essential thrombocythemia.
Sekiya Y; Okuno Y; Muramatsu H; Ismael O; Kawashima N; Narita A; Wang X; Xu Y; Hama A; Fujisaki H; Imamura T; Hasegawa D; Kosaka Y; Sunami S; Ohtsuka Y; Ohga S; Takahashi Y; Kojima S; Shimada A
Int J Hematol; 2016 Aug; 104(2):266-7. PubMed ID: 27209416
[No Abstract] [Full Text] [Related]
4. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.
Fu R; Liu D; Cao Z; Zhu S; Li H; Su H; Zhang L; Xue F; Liu X; Zhang X; Cheng T; Yang R; Zhang L
Leukemia; 2016 Mar; 30(3):746-9. PubMed ID: 26118316
[No Abstract] [Full Text] [Related]
5. Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience.
Luque Paz D; Mansier O; Riou J; Conejero C; Roy L; Belkhodja C; Ugo V; Giraudier S
Haematologica; 2019 Apr; 104(4):e134-e137. PubMed ID: 30337359
[No Abstract] [Full Text] [Related]
6. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia.
Shen H; Chao H; Ding Z; Feng Y; Cen J; Pan J; He J; Zhou M; Chen Z; Chen S
Leuk Lymphoma; 2015 Mar; 56(3):820-2. PubMed ID: 25005031
[No Abstract] [Full Text] [Related]
7. Mutations and thrombosis in essential thrombocythemia.
Guglielmelli P; Gangat N; Coltro G; Lasho TL; Loscocco GG; Finke CM; Morsia E; Sordi B; Szuber N; Hanson CA; Pardanani A; Vannucchi AM; Tefferi A
Blood Cancer J; 2021 Apr; 11(4):77. PubMed ID: 33907189
[No Abstract] [Full Text] [Related]
8. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
9. Searching for CALRity in myeloproliferative neoplasms.
Cook JR
Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
[No Abstract] [Full Text] [Related]
10. Essential thrombocythaemia.
Double G; Harrison C
Hematology; 2015 Mar; 20(2):119-20. PubMed ID: 25715049
[No Abstract] [Full Text] [Related]
11. Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis.
Chua CC; Omerod A; Wight J; Juneja S; Zantomio D
Pathology; 2018 Oct; 50(6):671-674. PubMed ID: 30097170
[No Abstract] [Full Text] [Related]
12. Clinical effect of CALR allele burden in patients with essential thrombocythemia.
Bertozzi I; Biagetti G; Vezzaro T; Barzon I; Carraro M; Fabris F; Randi ML
Ann Hematol; 2022 Jun; 101(6):1345-1346. PubMed ID: 34743237
[No Abstract] [Full Text] [Related]
13. Life, genes, and death in Ph- MPNs.
Silver RT
Blood; 2014 Oct; 124(16):2471-2. PubMed ID: 25323682
[TBL] [Abstract][Full Text] [Related]
14. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y; Shide K; Kameda T; Yamaji T; Sekine M; Kamiunten A; Akizuki K; Shimoda H; Tahira Y; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hashimoto K; Yamamoto S; Hasuike S; Hidaka T; Nagata K; Kitanaka A; Shimoda K
Ann Lab Med; 2017 Mar; 37(2):159-161. PubMed ID: 28029004
[No Abstract] [Full Text] [Related]
15. Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.
Nelson ND; Marcogliese A; Bergstrom K; Scheurer M; Mahoney D; Bertuch AA
Pediatr Blood Cancer; 2016 Aug; 63(8):1484-7. PubMed ID: 27100794
[TBL] [Abstract][Full Text] [Related]
16.
Wang SY; Yang N; Zhang LJ; Cheng ZY
Indian J Cancer; 2021; 58(3):431-433. PubMed ID: 34380850
[No Abstract] [Full Text] [Related]
17. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
18. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
19. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.
Kuykendall AT; Talati C; Padron E; Sweet K; Lancet JE; List AF; Sallman D; Komrokji RS
Am J Hematol; 2019 Dec; 94(12):E314-E317. PubMed ID: 31444809
[No Abstract] [Full Text] [Related]
20. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
